Literature DB >> 17484794

Respiratory controversies in the critical care setting. Conference summary.

Ira M Cheifetz1, Neil R MacIntyre.   

Abstract

Definitive evidence to settle the important clinical controversies we debated in this Journal Conference are not yet available. More randomized controlled trials are clearly needed for all of the topics presented. Additionally, neonatal and pediatric data are clearly lacking on most of these questions. The key points in many of the conversations on these controversial topics focused on the balance between efficacy and safety. When safety data exist without efficacy data, the uncontrolled variables often become the knowledge, experience, and support available in an individual intensive care unit. "New" therapies have the potential to help many patients but also have the potential to do great harm if clinicians do not follow standard guidelines and/or do not have the knowledge to use the therapy appropriately. It is clear that some current standards of care will be overthrown by future data while others will be finally substantiated. This Journal Conference queried the status quo to better enable clinicians to make informed decisions in the care of their critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484794

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  2 in total

1.  The evaluation of a non-invasive respiratory volume monitor in surgical patients undergoing elective surgery with general anesthesia.

Authors:  Christopher J Voscopoulos; C Marshall MacNabb; Jordan Brayanov; Lizeng Qin; Jenny Freeman; Gary John Mullen; Diane Ladd; Edward George
Journal:  J Clin Monit Comput       Date:  2014-07-19       Impact factor: 2.502

2.  Quantification of respiratory depression during pre-operative administration of midazolam using a non-invasive respiratory volume monitor.

Authors:  Luis N Gonzalez Castro; Jaideep H Mehta; Jordan B Brayanov; Gary J Mullen
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.